relatlimab,nivolumab
bms
['lung', 'sclc', 'relatlimab', 'nivolumab', 'nsclc', 'neopredict', 'able,(-kable),(-eable)', 'nivo', 'medsir']
dr. martin schuler discussed the feasibility and efficacy of pd-1(nivolumab) and lag-3(relatlimab) targeting prior to resection in pts with curatively resectable nsclc (neopredict-lung study). results: r0 resection rate: 98%; 12 months os: 96% (95% ci: 83-99%). #esmo2022 
Bring your idea to life??Creating successful IITs & optimal drug development??Medica Scientia Innovation Research????????https://t.co/cciUf0lqpM